Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,067 recruiting studies in this area right now.
By phase
- Not applicable3,005
- Phase 21,060
- Phase 1794
- Phase 1/Phase 2441
- Phase 3435
- Phase 4233
- Phase 2/Phase 399
Top conditions
- Multiple Sclerosis330
- Multiple Myeloma328
- Asthma194
- Lymphoma179
- Type 1 Diabetes132
- Rheumatoid Arthritis131
- Atopic Dermatitis122
- Systemic Lupus Erythematosus121
- Acute Lymphoblastic Leukemia118
- HIV Infections105
- Chronic Lymphocytic Leukemia96
- Autoimmune Diseases79
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Hodgkin Lymphoma64
- Diabetes Mellitus, Type 163
- Leukemia63
- Type 1 Diabetes Mellitus63
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca64
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic50
- City of Hope Medical Center49
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California498
- Maryland198
- Alabama178
- Florida151
- Arizona150
- Massachusetts118
- New York114
- Texas112
- Illinois84
- Colorado81
Recruiting studies6,067 total
- NCT04139304RecruitingEarly Phase 1
Study of daratumumab with EPOCH for plasmablastic lymphoma
This early-phase trial tests daratumumab combined with a dose-adjusted chemotherapy plan (EPOCH) to treat plasmablastic lymphoma. It aims to improve how well the cancer responds, including in people living with HIV or without HIV.
Miami, FloridaAges 18 years+ - NCT04094610RecruitingPhase 1/Phase 2
Repotrectinib for kids with certain cancer gene changes
This early-phase study tests repotrectinib, a targeted medicine, in children and young adults whose tumors have specific gene changes involving ROS1 or NTRK. It may help shrink advanced cancers that carry these gene alterations.
Los Angeles, CaliforniaAges Up to 25 years - NCT04138927Enrolling by invitationPhase 3
Long-term fostamatinib use for warm autoimmune anemia
This study checks the benefits and safety of continuing fostamatinib over the long term for people with warm autoimmune hemolytic anemia. It may help by reducing the body’s immune attack on red blood cells, and it’s designed for people who already finished a prior part of the study.
Los Angeles, CaliforniaAges 18–100 - NCT04094311RecruitingPhase 3
Testing a modified cell therapy when product quality is off-spec
This study looks at using tisagenlecleucel, a cell therapy, when the final product does not meet routine “commercial release” quality standards. It focuses on whether it can still be given safely and effectively to people with serious or life-threatening illness.
Hamilton, OntarioAges birth–100 years - NCT04068597RecruitingPhase 1/Phase 2
Testing inobrodib for blood cancers that came back
This is an early-stage study of inobrodib (CCS1477) for blood cancers like lymphoma, multiple myeloma, or acute myeloid leukemia that have returned or did not respond to standard treatment. It aims to see whether the drug is safe and can help control the cancer.
Atlanta, GeorgiaAges 18 years+ - NCT04065399RecruitingPhase 1/Phase 2
Testing revumenib for relapsed acute leukemia with certain gene changes
This trial tests revumenib, a targeted medicine, to treat acute leukemia that has come back or hasn’t fully gone away. It may help people whose leukemia has specific gene changes (like KMT2A or NPM1) by trying to better control the cancer.
Duarte, CaliforniaAges 4 weeks+ - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
Tampa, FloridaAges 18 years+ - NCT04047641RecruitingPhase 1/Phase 2
Quizartinib with chemotherapy for new or returning leukemia
This trial tests a combination of anti-leukemia drugs (including quizartinib) together with chemotherapy for people with acute myeloid leukemia (AML), a rare mixed-type leukemia, or high-risk myelodysplastic syndrome (MDS). It may help by trying to better control cancer in people whose disease is newly diagnosed or has returned/not responded to prior treatment.
Houston, TexasAges 18 years+ - NCT04045470Recruiting
Skin-device test to find drugs for T-cell lymphoma lesions
This trial tests a tiny device placed directly into skin lymphoma spots to help identify which “candidate” drugs could work. It’s mainly aimed at people with measurable skin involvement from T-cell lymphoma, after they stop certain treatments for a set time.
Boston, MassachusettsAges 18 years+ - NCT04095156Recruiting
Study of immune B cells in membranous nephropathy
This study looks at immune “B cells” in people with membranous nephropathy (a kidney disease). It includes people who have received or are being considered for B-cell–depleting treatment, aiming to better understand what drives the disease and how it may respond.
Ranica, BGAges 18 years+ - NCT04028531Recruiting
Understanding chronic lymphocytic leukemia in clinic patients
This study aims to learn more about chronic lymphocytic leukemia (CLL) and closely related conditions. It may help researchers better understand who gets CLL and how it behaves over time, which can improve future care.
Boston, MassachusettsAges 18 years+ - NCT04142047Recruiting
Study muscle energy and fatigue in older adults
This study measures how older adults’ muscles use energy and how easily they tire during activity. It includes both people with HIV (with stable treatment and an undetectable viral load) and people without HIV to better understand differences in fatigue.
Baltimore, MarylandAges 60–90 - NCT04043494RecruitingPhase 3
Study of new treatment plans for childhood lymphoblastic lymphoma
This trial studies a treatment approach for children and teens newly diagnosed with lymphoblastic lymphoma. It may help doctors choose therapies based on genetic risk information from lab testing done on tumor samples.
GrazAges Up to 18 years - NCT04077307RecruitingPhase 1
Karonudib for leukemia that has come back or not responded
This Phase 1 trial studies Karonudib, a new treatment, for people with leukemia (and a few related blood cancers) that has come back or didn’t respond to standard care. The goal is to see if the treatment is safe and to learn how it may work in this hard-to-treat setting.
AarhusAges 18–75 - NCT04049084Enrolling by invitation
Follow-up study for people treated with gene therapy for ADA-SCID
This is a follow-up (no new treatment) study for people who previously received a gene therapy made from their own cells for ADA-SCID. It mainly tracks long-term safety and whether a marker showing the gene change can still be found.
Los Angeles, CaliforniaAges Any age - NCT04083183RecruitingPhase 1/Phase 2
Testing radiation plus antibody therapy for certain non-cancer diseases
This early-phase study tests a conditioning treatment using total-body irradiation and a radioactive antibody (called astatine-211) before a stem cell transplant for non-cancer conditions. The goal is to improve how well the donor cells take hold and are tolerated.
Seattle, WashingtonAges 18–49 - NCT04083495RecruitingPhase 2
CAR T treatment for relapsed CD30-positive T-cell lymphoma
This trial tests a lab-made immune therapy (CAR T cells) for lymphoma that has come back or did not respond to treatment, specifically CD30-positive T-cell lymphoma. The goal is to shrink the cancer and help keep it under control after previous therapies, including people who have relapsed after stem cell transplant.
Chapel Hill, North CarolinaAges 18–99 - NCT04119713Recruiting
Study how the immune system changes after cancer immunotherapy
This study looks at what happens to your immune system after you start a type of cancer treatment called a checkpoint inhibitor. The goal is to better understand side effects related to “autoimmunity” (when the immune system starts attacking the body) and improve care.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04106830Recruiting
Study to follow neuroinflammation and demyelination diseases with imaging
This study builds a China-based group of people with neuroinflammatory and demyelination diseases and collects health and MRI (brain scan) information. It may help doctors better understand these conditions over time and improve future treatments.
Beijing, Beijing MunicipalityAges 16–75 - NCT04045587Recruiting
Registry for severe asthma in adults in Canada
This is a research registry that collects health information from adults with severe asthma to better understand how the condition behaves and how treatments are used. You may be able to take part if your asthma is considered severe and is not well controlled.
Edmonton, AlbertaAges 18 years+ - NCT03937635RecruitingPhase 3
Lenalidomide and dexamethasone, with or without daratumumab
This phase 3 trial studies whether lenalidomide plus dexamethasone can prevent or delay progression of “high-risk smoldering” multiple myeloma, and whether adding daratumumab improves outcomes. It’s meant for people who are not yet showing symptoms, but whose lab and scan results suggest higher risk.
Birmingham, AlabamaAges 18 years+ - NCT03959085RecruitingPhase 3
Inotuzumab plus chemotherapy for high-risk childhood leukemia
This Phase 3 trial tests whether adding inotuzumab to standard post-induction chemotherapy improves outcomes for children and young teens with high-risk B-ALL, mixed phenotype acute leukemia (MPAL), or certain high-risk B-LLy. It may help by targeting leukemia cells more directly, but participation depends on specific age, lab results, and medical history rules.
Birmingham, AlabamaAges 12 months–25 years - NCT03949855RecruitingPhase 2
Belimumab plus rituximab for primary membranous nephropathy
This study tests whether adding belimumab to rituximab helps people with primary membranous nephropathy (a kidney disease) that has the right blood test marker and specific protein levels. The goal is to improve kidney outcomes and reduce disease activity while keeping treatment safe.
Birmingham, AlabamaAges 18–75 - NCT04002947RecruitingPhase 2
Acalabrutinib with chemo for untreated aggressive B-cell lymphoma
This Phase 2 trial studies whether adding acalabrutinib to intensive chemo (DA-EPOCH-R or R-CHOP) works better for people newly diagnosed with aggressive diffuse large B-cell lymphoma (DLBCL) or related high-grade B-cell lymphomas. It may help shrink cancer and control the disease by targeting lymphoma in two different ways.
Bethesda, MarylandAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,067 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,241 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.